glp 1 shortage FDA says that the GLP-1 is over GLP-1 Drugs Driving Protein Demand

BMI measurements are counted at the start of GLP-1 therapy, so even people who fall below the threshold now can qualify if they can show they had a high enough BMI when they began taking the drugs

The prevalence of GLP-1 agonist use is notably higher, reaching 43% among adults diagnosed with diabetes, 25% among those with heart disease, and 22% among those recently diagnosed as overweight or obese in the past five years

[DOI] [PubMed] [Google Scholar] 140.Arone L.J., Mackintosh R., Rosenbaum M., Leibel R.L., Hirsch J

In the Pioneer 1 study, participants took daily oral semaglutide at doses of 3 mg, 7 mg, or 14 mg, or a placebo

Glucagon-like Peptide-1 Receptor-Based Therapeutics for Metabolic Liver Disease

15 Bariatric surgery Bariatric surgery is a highly effective treatment for obesity, often leading to more pronounced and sustained weight loss than GLP-1 RAs (mean difference: 22.7 kg, 95% CI 31.4, 14.0) 16 and pharmalogical treatment as a whole (22.1 kg, 95% CI 28.9, 15.2)